In feed-mill production of a flubendazole 5% w/w premix for porcine medication, the starting Flubenol veterinary-grade API is a white to off-white crystalline powder with a benzimidazole carbamate structure and very low aqueous solubility at neutral pH. The received material is checked for residual solvents against ICH Q3C limits and for related substances by liquid chromatography according to Ph. Eur. 2.2.29 before any blending. Milled API is pre-blended with a lactose monohydrate or wheat-semolina carrier using stepwise geometric dilution in a ribbon blender; the selected D90 window of 20–40 µm is measured by laser diffraction according to ISO 13320 because finer particles increase dusting and electrostatic adhesion to stainless steel surfaces, while coarser particles above 75 µm demix from the carrier during transfer through bucket elevators and screw conveyors. A vegetable-oil binder is sprayed at a rate not exceeding 0.5 L per 100 kg blend to bind fines without forming lumps that cannot pass a 500 µm sieve. Homogeneity is evaluated at 15, 20, and 25 min mixing intervals from 10 defined positions; the plateau is defined as the mixing time at which assay RSD remains at or below 3.0%. Release testing must be accompanied by a validated cleaning procedure because cross-contamination into subsequent non-medicated feed is controlled under Regulation (EU) 2019/4 Annex II, and flubendazole particles show preferential adhesion to plastic rotary valve seals. The carryover acceptance limit is established at 1% of the maximum authorised content in the previous medicated feed for non-target feed, and the flush material after product changeover is assayed before line release.

What Limits Direct Compression of Flubendazole Tablets for Avian or Small-Animal Dosing?

Direct compression of flubendazole API is constrained by its needle-like crystal habit, low bulk density, and high interparticulate friction. At API loadings above 30% w/w, rotary tablet press trials at 50 rpm often show weight variability caused by poor flow into the die; precompression force in the 5–10 kN range and main compression force in the 20–25 kN range may still produce capping unless a dry binder such as pregelatinised starch is included at 5% w/w. A more reproducible route is wet granulation of milled flubendazole with D90 ≤ 25 µm, lactose monohydrate, microcrystalline cellulose, crospovidone 4% w/w, and magnesium stearate 0.5% w/w. The granules are dried to a loss-on-drying endpoint of 1.5–2.5% w/w and compacted to hardness between 40 N and 60 N. Disintegration is tested by Ph. Eur. 2.9.1 in 900 mL water at 37 ± 2 °C and should not exceed 15 min. Dissolution testing uses 0.1 M hydrochloric acid with 0.5% sodium dodecyl sulfate at 75 rpm paddle speed, with a Q value of 75% released at 45 min; for avian species with short gastrointestinal transit, pH 6.8 phosphate buffer with surfactant is more discriminative. Content uniformity is assessed by Ph. Eur. 2.9.40 with an acceptance value not exceeding 15.0.

When flubendazole is formulated as a water-dispersible powder or granule for poultry drinking water, the wetting and binder system is selected around the API’s pH-dependent solubility. High-shear granulation with lactose monohydrate, povidone 3% w/w, and sodium lauryl sulfate 0.5% w/w produces granules that wet within 120 s when 20 g is added to 1 L of hard water at 300 ppm calcium carbonate equivalent and stirred at 100 rpm. The pH of the finished dispersion is buffered between 4.0 and 5.5 with citric acid and disodium phosphate because flubendazole solubility falls sharply above pH 5.5; acidification below pH 2.5 creates a clear but unpalatable solution that can reprecipitate at drinker outlets when the line water pH rises above 6.5. Particles larger than 150 µm must be removed by wet screening because they clog nipple drinker valves; if the granule D90 exceeds 50 µm, a wet-milling step with 0.8–1.2 mm zirconia beads in a ball mill is applied. Sedimentation volume after 24 h is measured in a 100 mL cylinder and should remain above 0.90 relative to the initial volume. Sodium metabisulphite at 0.1% w/w is added as an oxygen scavenger to slow oxidative degradation of the benzimidazole ring in warm drinking water; higher concentrations can reduce palatability. Redispersibility is confirmed by three manual inversions, with no solid cake remaining.

If the Targeted Presentation Is a Sterile Injectable Suspension, Terminal Moist Heat Sterilization Can Shift Polymorph Ratio and Crystal Habit

Flubendazole is practically insoluble in aqueous media at pH 6.8, so parenteral presentations are suspensions rather than true solutions. A sterile injectable suspension is manufactured by dispersing micronised API with D90 ≤ 10 µm in a vehicle containing sodium carboxymethylcellulose 0.5% w/w, polysorbate 80 0.1% w/w, and benzyl alcohol 1.0% v/v. The suspension is filled under nitrogen into glass vials with chlorobutyl rubber stoppers. Terminal moist-heat sterilisation at 121 °C for 15 min may trigger crystal growth and polymorph conversion; therefore the D90 and X-ray diffractogram of the terminal batch must be compared to the pre-sterilisation suspension. An increase of more than 30% in volume-median diameter after autoclaving is a batch rejection criterion because larger crystals settle rapidly and may cause tissue irritation. Syringeability is tested through a 21 G needle by ISO 7886-1 using a constant rate of 50 mm/min; a force exceeding 25 N indicates needle blockage or excessive viscosity. If polymorph conversion is detected by differential scanning calorimetry per Ph. Eur. 2.2.34, the suspension may be prepared by aseptic filtration of the vehicle and gamma irradiation of the micronised API. Published data on flubendazole particulate behaviour during steam sterilisation are limited; pre-formulation studies should include powder X-ray diffraction and differential scanning calorimetry before terminal sterilisation is selected.

Capsule Filling and Powder Layering Dynamics for Low-Dose Flubendazole Capsules

Low-dose flubendazole capsules, typically in the 5–25 mg range, require geometric dilution because the API has poor flow and can segregate from coarse excipients. The bulk blend is prepared by mixing milled flubendazole with lactose monohydrate, colloidal silicon dioxide 0.5% w/w, and magnesium stearate 0.5% w/w in a V-blender at 60–80% fill volume for 20 min; extended blending with magnesium stearate beyond 30 min reduces dissolution due to hydrophobic film formation on the drug particles. Powder conditioned at 30–35% relative humidity shows less sticking to gelatin capsule walls, while HPMC capsules are preferred in tropical packaging because their lower equilibrium moisture reduces shell brittleness and API agglomeration. Capsule filling on a dosator machine uses pin settings selected to deliver a fill weight with a relative standard deviation below 2.0%; powder bed depth is controlled to avoid particle size stratification. Content uniformity is tested by Ph. Eur. 2.9.40 with an acceptance value not exceeding 15.0, and dissolution is performed by Ph. Eur. 2.9.3 in 0.1 M hydrochloric acid with 0.5% sodium dodecyl sulfate. The use of sodium lauryl sulfate in the capsule blend at 0.2% w/w improves wetting of the hydrophobic API, but higher amounts can produce foaming in the dissolution test and mask differences between batches.

Non-sterile oral solutions of flubendazole are feasible only when the vehicle is acidified or co-solventised because the API is practically insoluble at neutral pH. A vehicle containing 20% v/v propylene glycol, 10% v/v ethanol, and 0.05 M hydrochloric acid to pH 2.8–3.2 can hold flubendazole at 10 mg/mL under controlled room temperature; exact solubility data must be generated at 2–8 °C because flubendazole precipitates at lower temperatures. The solution is passed through a 0.45 µm polyvinylidene fluoride membrane before filling into amber polyethylene terephthalate bottles because the benzimidazole ring is light-sensitive. Potable water dilution at the farm causes precipitation unless the diluent contains buffering acid; therefore the label instructs use of a 0.1% citric acid solution as the diluent. Assay and related substances are monitored by HPLC per Ph. Eur. 2.2.29, with total related substances not exceeding 1.0% area at the end of shelf-life unless the marketing authorisation specifies a tighter limit. pH is measured by Ph. Eur. 2.2.3 and should remain within ±0.1 unit of the registered value.

Recovered Flubendazole Residues in Multi-Product Feed Mills Can Trigger Batch Recalls Without Quantitative Cleaning Validation

Flubendazole recovery from feed manufacturing surfaces is complicated by its electrostatic behaviour and poor water solubility at neutral pH. Dry cleaning alone leaves residues in ribbed rubber seals, plastic bucket elevator cups, and painted metal surfaces; validated cleaning therefore includes wet washing with a mildly acidic detergent followed by a rinse with 0.1% citric acid solution to solubilise the API before it reprecipitates. Swab sampling from a 10 cm × 10 cm surface is performed after cleaning and analysed by HPLC; the residue limit is derived from the lowest permitted inclusion in the next species feed and the smallest batch size manufactured on that line. The sampling plan must include drag conveyor joints, mixer discharge gates, and dust-collection ducting because flubendazole concentrates in dedusting filter socks. Release of the non-medicated batch is blocked until all samples fall below the derived carryover limit. Changeover validation under Regulation (EU) 2019/4 Annex II must demonstrate that residues in the first non-medicated batch do not exceed the permitted carryover level, and a worst-case product with high inclusion rate is used as the validation challenge. Documentation should include HPLC chromatograms from the flush, swab location diagrams, and a mass-balance calculation; failure to maintain these records can force a recall if a non-target species batch tests above the extrapolated carryover threshold.